| Literature DB >> 21603104 |
Abstract
Patients with CRF usually progress through different stages before they reach ESRD and require special medical, social and psychological care and support during the pre-ESRD and following renal replacement therapy (RRT). Early referral of patients with CRF has the advantage of receiving adequate management and regular followup, with significant reduction in cardiovascular morbidity and mortality, attending an education program, prepared psychologically, participate in the decision of type of RRT, preemptive kidney transplantation, early creation of dialysis access, and adequate training in selected modality of RRT. During the early stages of commencement of RRT, psychological support and social care with rehabilitation program are mandatory. The degree of involvement and interaction must be individualized according to the needs of patient and type of RRT. A multidisciplinary team is crucial for implementation of a variety of strategies to help staff intervene more effectively in meeting the care needs of CRF patients.Entities:
Year: 2011 PMID: 21603104 PMCID: PMC3097050 DOI: 10.4061/2011/639840
Source DB: PubMed Journal: Int J Nephrol
Stages of chronic kidney disease: KDIGO classification of CKD (1).
| Stage | Description | GFR (mL/min/1.73 m2) |
|---|---|---|
| (1) | Kidney damage with normal or ↑ GFR | ≥90 |
| (2) | Kidney damage with mild ↓ GFR | 60–89 |
| (3) | Moderate ↓ GFR | 30–59 |
| (4) | Severe ↓ GFR | 15–29 |
| (5) | Kidney failure | <15 (or dialysis) |
Chronic kidney disease is defined as either kidney damage or GFR <60 mL/min/1.73 m2 for ≥3 months. Kidney damage is defined as pathologic abnormalities or markers of damage, including abnormalities in blood or urine tests or imaging studies.
KDIGO: The Kidney Disease Improving Global Outcomes; CKD: Chronic kidney disease; GFR: Glomerular filtration rate.
Benefits of early referral of patients with chronic kidney disease.
| (1) | Prevention and management of CKD modifiable risk factors |
| (2) | Optimization of treatment of CKD |
| (3) | Preservation of functioning nephrons and delaying the progression of renal failure |
| (4) | Access to structured psychoeducational program |
| (5) | Adaptation of CKD patient to RRT treatment |
| (6) | Preparation and creation of suitable dialysis access with less temporary vascular access |
| (7) | Training on selected modality of RRT with better compliance |
| (8) | Preemptive kidney transplantation |
| (9) | Reduction of cardiovascular morbidity and mortality |
| (10) | Reduction of costs |
Primary healthcare physician should ideally refer patients with CKD at stage 1 if haematuria or significant proteinuria present, at stage 2 if eGFR declines >4 mL/min/year and at stage 3 for all patients with CKD, where eGFR <60 mL/min/1.73 m2.
CKD: chronic kidney disease; RRT: renal replacement therapy; eGFR: estimated glomerular filtration rate.
(a) HD treatment goals or HD clinical performance measures
| (1) | Prevalance of AV Fistula |
| (2) | Dialysis ≥3 times/week |
| (3) | Dialysis duration ≥4 hr |
| (4) | Arterial blood flow rate (QB) ≥ 300 mL/min |
| (5) | Kt/V ≥ 1.4 |
| (6) | Intradialytic body weight gain <4% |
| (7) | Mean arterial BP ≤ 105 mmHg |
| (8) | Transferrin Saturation = 30–50% |
| (9) | Serum Ferritin = 200–500 ng/mL |
| (10) | Hemoglobin = 10–12 gm/dL |
| (11) | Phosphorus = 3.5–5.5 mg/dL |
| (12) | Calcium = 8.8–10 mg/dL |
| (13) | Calcium X Phosphorus < 55 mg2/dL2 |
| (14) | PTH = 150–600 pg/mL |
| (15) | Serum albumin > 3.5 gm/dL |
| (16) | Bicarbonate > 20 mEq/L |
| (17) | Hepatitis B & C seroconversion = 0% |
HD: hemodialysis; AV Fistula: arteriovenous fistula; Kt/v: hemodialysis adequacy; BP: blood pressure; PTH: parathyroid hormone.
(b) PD treatment goals or PD clinical performance measures
| (1) | Total (residual kidney + peritoneal) Kt/Vurea ≥ 1.7 per week or total creatinine clearance ≥ 50 L/week/1.73 m2 |
| (2) | Peritoneal net ultrafiltration in anuric patients ≥ 1.0 L/day |
| (3) | Albumin ≥ 3.5 g/dL |
| (4) | Hemoglobin ≥ 10.0 and ≤ 12.0 g/dL |
| (5) | Transferrin saturation = 30–50% |
| (6) | Serum ferritin ≥ 200 and ≤500 |
| (7) | Phosphorus ≥ 3.5 and ≤ 5.5 mg/dL |
| (8) | Calcium × Phosphorus < 55 mg2/dL2 |
| (9) | Intact PTH ≥150 and ≤600 pg/mL |
| (10) | Predialysis mean arterial blood pressure < 105 mmHg |
| (11) | Clinic peritonitis rate <1 episode/24 patient-months |
| (12) | Hepatitis B & C seroconversion = 0% |
PD: peritoneal dialysis; Kt/v: hemodialysis adequacy; PTH: parathyroid hormone.